Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors

Status:
Terminated

Trial end date:
2018-01-24

Target enrollment:

Participant gender:

The objective of this study is to determine the safety, pharmacokinetics, maximum tolerated dose/recommended Phase 2 dose, and efficacy of PLX7486.

Phase 1

Plexxikon